FRFarzad Rahmani

Farzad Rahmani

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Farzad Rahmani has a total of 229 co-authors. Here are the top co-authors by number of shared publications:

  • Amir Avan

    Medical Genetics Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

    28 shared publications
  • Seyed Mahdi Hassanian

    Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran; Department of Medical Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

    24 shared publications
  • Gordon A. Ferns

    Division of Medical Education, Brighton & Sussex Medical School, Falmer, Brighton, UK

    20 shared publications
  • Majid Khazaei

    Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

    14 shared publications
  • Amir Avan

    Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

    11 shared publications
  • Atena Soleimani

    Department of Clinical Biochemistry, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

    11 shared publications

Latest Publications

  • Open Access

    Interplay between lncRNA/miRNA and Wnt/β-catenin signaling in brain cancer tumorigenesis

    by Farzad Rahmani, Abdulridha Mohammed Al-Asady, Reyhane Hanaie, Mehrdad Zandigohar, Homeira Faridnejad, Mahya Payazdan, Pegah Safavi, Mikhail Ryzhikov, Seyed Mahdi Hassanian

    Brain cancers are among the most aggressive malignancies with high mortality and morbidity worldwide. The pathogenesis of brain cancers is a very complicated process involving various genetic mutations affecting several oncogenic signaling pathways like Wnt/β-catenin axis. Uncontrolled activation of this oncogenic signaling is associated with decreased survival rate and poor prognosis in cancer patients. Long non-coding RNAs (lncRNAs) and microRNAs (miRNAs) were shown to play important roles in regulating cell proliferation, differentiation, and apoptosis by regulating the expression of their target genes. Aberrant expression of these non-coding RNAs (ncRNAs) was reported in many human cancers, including glioblastoma, medulloblastoma, meningioma, and pituitary adenoma. Multiple lncRNAs were shown to participate in brain tumor pathogenesis by targeting Wnt signaling regulatory miRNAs. SNHG7/miR-5095, PCAT6/miR-139-3p, SNHG6/miR-944, SNHG1/ miR-556‐5p, SNHG17/ miR-506-3p, LINC00702/miR-4652-3p, DLGAP1-AS1/miR-515-5p, HOTAIR/miR-1, HOTAIR/miR-206, CRNDE/miR-29c-3p, AGAP2-AS1/ miR-15a/b-5p, CLRN1-AS1/miR-217, MEG3/miR-23b-3p, and GAS5/miR-27a-5p are identified lncRNA/miRNA pairs that are involved in this process. Therefore, recognition of the expression profile and regulatory role of ncRNAs on the Wnt signaling may offer a novel approach to the diagnosis, prognosis, and treatment of human cancers. This review summarizes previous data on the modulatory role of lncRNAs/miRNAs on the Wnt/β-catenin pathway implicated in tumor growth, EMT, metastasis, and chemoresistance in brain cancers.


  • The recent insight in the release of anticancer drug loaded into PLGA microspheres

    by Farzad Rahmani, Saghi Naderpour, Behnam Ghorbani Nejad, Milad Rahimzadegan, Zivar Nejad Ebrahimi, Hossein Kamali, Rahim Nosrati

    Cancer is a series of diseases leading to a high rate of death worldwide. Microspheres display specific characteristics that make them appropriate for a variety of biomedical purposes such as cancer therapy. Newly, microspheres have the potentials to be used as controlled drug release carriers. Recently, PLGA-based microspheres have attracted exceptional attention relating to effective drug delivery systems (DDS) because of their distinctive properties for a simple preparation, biodegradability, and high capability of drug loading which might be increased drug delivery. In this line, the mechanisms of controlled drug release and parameters that influence the release features of loaded agents from PLGA-based microspheres should be mentioned. The current review is focused on the new development of the release features of anticancer drugs, which are loaded into PLGA-based microspheres. Consequently, future perspective and challenges of anticancer drug release from PLGA-based microspheres are mentioned concisely. Graphical abstract


  • Open Access

    The interplay between non-coding RNAs and Wnt/β-catenin signaling pathway in urinary tract cancers

    by Farzad Rahmani, Pegah Safavi, Ayda Fathollahpour, Fatemeh Tanhaye Kalate Sabz, Parastoo Tajzadeh, Mohsen Arefnezhad, Gordon A. Ferns, Seyed Mahdi Hassanian, Amir Avan

    Non-coding RNAs (ncRNAs) are emerging as important regulators in various pathological conditions including tumorigenesis, metastasis, and drug resistance in human cancers. Oncogenic or tumor suppressor ncRNAs exert prominent effects on cell proliferation, migration and invasion in cancer cells through modulating various signaling pathways including Wnt/β-catenin. Upregulation of the oncogenic Wnt/β-catenin pathway was reported to be implicated in multiple human cancers including breast, liver, colorectal, and urothelial cancers. Therefore, identifying interactions between ncRNAs and canonical Wnt signaling components may represent novel therapeutic targets for better treatment and management of cancer. In this review, we summarized the recent findings about miRNA/lncRNA-dependent mechanisms that regulate Wnt/β-catenin signaling involved in tumorigenesis and metastasis of urinary tract cancers.


  • Open Access

    Inhibition of angiotensin II type 1 receptor by candesartan reduces tumor growth and ameliorates fibrosis in colorectal cancer

    by Ehsan Tabatabai, Majid Khazaei, Fereshteh Asgharzadeh, Seyedeh Elnaz Nazari, Neda Shakour, Hamid Fiuji, Aghigh Ziaeemehr, Asma Mostafapour, Mohammad Reza Parizadeh, Mohammad Nouri, et al.

    Colorectal cancer (CRC) is an important cause of cancer-related mortality. Aberrant activation of the renin-angiotensin system (RAS) is reported to be associated with poor clinical outcomes in patients with CRC. This study was designed to explore the anti-tumor effects of the angiotensin receptor blocker Candesartan either alone or in combination with 5-FU in in vitro and in vivo models of CRC. The cytotoxic effects of Candesartan were assessed using the MTT assay in two colorectal cancer cell lines (CT-26 and SW-480). To investigate the potential regulatory role of Candesartan on tumor growth, apoptosis, and migration, the expression levels of Cyclin D1, Survivin, MMP3, MMP9, and E-cadherin mRNAs were evaluated. The oxidant/antioxidant balance was also examined by determining the levels of MDA, thiols, SOD, and CAT. We used a xenograft model of colon cancer to investigate the effects of Candesartan alone, or in combination with 5-FU, on tumor growth following histological staining (Hematoxylin & Eosin and Masson trichrome staining) and biochemical studies as well as gene expression analyses by RT-PCR and western blotting. Candesartan suppressed tumor cell proliferation and migration by modulating Cyclin D1, MMP3/9, and E-cadherin. Treatment with Candesartan either alone, or in combination with 5-FU decreased tumor size in the mouse model, and also increased the level of oxidative markers MDA and reduced CAT, SOD, and thiols. Histological evaluation showed that Candesartan increased tumor necrosis, reduced tumor density and attenuated collagen deposition reducing tumor fibrosis in tumor xenograft. Candesartan, an inhibitor of the RAS, when used in combination with 5-FU reduced tumor growth by inhibiting fibrosis and inducing ROS production, supporting further clinical studies on this therapeutic approach for treatment of CRC.


  • Open Access

    Inhibition of transforming growth factor-beta by Tranilast reduces tumor growth and ameliorates fibrosis in colorectal cancer

    by Milad Hashemzehi, Negar Yavari, Farzad Rahmani, Fereshteh Asgharzadeh, Atena Soleimani, Neda Shakour, Amir Avan, Farzin Hadizadeh, Maryam Fakhraie, Reyhaneh Moradi Marjaneh, et al.

    Transforming Growth Factor-beta (TGF-β) is dysregulated in colorectal cancer and there is growing evidence that it is associated with a poor prognosis and chemo-resistance in several malignances, including CRC. In this study we have explored the therapeutic potential of targeting TGF-β using Tranilast in colon cancer. The anti-proliferative activity of Tranilast was evaluated in 2- and 3-dimensional cells. We used a xenograft model of colon cancer to investigate the activity of Tranilast alone or in combination with 5-FU on tumor growth using histological staining and biochemical studies, as well as gene expression analyses using RT-PCR and Western blotting. Tranilast alone or in combination with 5-FU inhibited tumor growth and was associated with a reduction of TGF-β expression and CD31 positive endothelial cells. Histological evaluation showed that Tranilast increased tumor necrosis and reduced tumor density and angiogenesis. Tranilast increased MDA and ROS production. It was also found that Tranilast reduced total thiol concentration and reduced SOD and catalase activity. Tranilast plus 5-FU was also found to attenuate collagen deposition, reducing tumor fibrosis in tumor xenografts. Our results show that Tranilast, a TGF inhibitor, in combination with 5-FU reduces tumor growth by inhibiting fibrosis and inducting ROS, thus supporting this therapeutic approach in CRC treatment.


  • Open Access

    Angiotensin receptor blocker Losartan inhibits tumor growth of colorectal cancer

    by Milad Hashemzehi, Farzad Rahmani, Mahdieh Khoshakhlagh, Amir Avan, Fereshteh Asgharzadeh, Farnaz Barneh, Reyhaneh Moradi-Marjaneh, Atena Soleimani, Hamid Fiuji, Gordon A. Ferns, et al.

    The renin-angiotensin system (RAS) is up-regulated in patients with colorectal cancer (CRC) and is reported to be associated with poor prognosis and chemo-resistance. Here we explored the therapeutic potential of targeting RAS in CRC using Losartan, an angiotensin receptor blocker. An integrative-systems biology approach was used to explore a proteome-level dataset of a gene signature that is modulated by Losartan. The anti-proliferative activity of Losartan was evaluated using 2- and 3-dimensional cell culture models. A xenograft model of colon cancer was used to investigate tumor growth with Losartan alone and in combination with 5-FU followed by histological staining (Hematoxylin & Eosin and Masson trichrome staining), biochemical analyses, gene expression analyses by RT-PCR, western blot/IHC, or MMP Gelatin Zymography studies. Effects on cell cycle and cell death were assessed by flow cytometry. Losartan inhibited cell growth and suppressed cell cycle progression, causing an increase in CRC cells in the G1 phase. Losartan significantly reduced tumor growth and enhanced tumor cell necrosis. An impact on the inflammatory response, including up-regulation of pro-inflammatory cytokines and chemokines in CRC cells are potential mechanisms that could partially explain Losartan’s anti-proliferative effects. Moreover, metastasis and angiogenesis were reduced in Losartan-treated mice as observed by inhibited matrix metalloproteinase-2 and -9 activities and decreased tumor vasculature. These data demonstrate the therapeutic potential of combining chemotherapeutic regimens with Losartan to synergistically enhance its activity and target the renin-angiotensin system as a new approach in colorectal cancer treatment.


  • Association of a variant in the tumor necrosis factor alpha gene with risk of cervical cancer

    by Negin Behboodi, Marjaneh Farazestanian, Azam Rastgar-Moghadam, Mehrane Mehramiz, Ehsan Karimi, Majid Rajabian, Farzad Rahmani, Shadi Khorrami, Amirhosein Jafarian, Noorieh Sharifi-Sistani, et al.

    Tumor necrosis factor alpha (TNF-α) is a pro-inflammatory cytokine involved in the regulation of the immune system and potentially the progression of cervical neoplastic lesions. In this study, we aimed to explore the possible relationship between polymorphisms of the TNF-α gene and susceptibility to cervical cancer. The relationship between a single nucleotide polymorphism (SNP) in the TNF-α gene (rs1800629) and the risk of cervical cancer was evaluated in a total of 445 subjects with (n = 153), or without (n = 292) cancer. Genotyping was performed using a Taq-Man based real time PCR method. Logistic regression analysis showed that individuals with AG/AA genotypes had an increased risk of cervical cancer compared to those with a GG genotype (OR 3.79, 95% CI 2.4–5.7, < 0.001). Our findings demonstrated that a genetic variant in the TNF-α gene (rs1800629) was associated with increased level and risk of developing cervical cancer, suggesting its potential use as a genetic risk factor for cervical neoplasia.


  • Role of regulatory miRNAs of the Wnt/ β-catenin signaling pathway in tumorigenesis of breast cancer

    by Farzad Rahmani, Ayda Tadayyon Tabrizi, Pedram Hashemian, Sajede Alijannejad, Hossein Ali Rahdar, Gordon A Ferns, Seyed Mahdi Hassanian, Soodabeh Shahidsales, Amir Avan


  • The diagnostic, prognostic and therapeutic potential of circulating microRNAs in ovarian cancer

    by Hamideh Aboutalebi, Afsane Bahrami, Atena Soleimani, Nikoo Saeedi, Farzad Rahmani, Majid Khazaei, Hamid Fiuji, Mojtaba Shafiee, Gordon A. Ferns, Amir Avan, et al.


  • Association of a genetic variant in the angiopoietin-like protein 4 gene with cervical cancer

    by Farzad Rahmani, Malihe Hasanzadeh, Seyed Mahdi Hassanian, Majid Khazaei, Habibollah Esmaily, Seyed Ami Asef-Agah, Alireza Naghipour, Gordon A Ferns, Amir Avan